Version:

02-04-2014 01-01-2018: Changes in Adult vaccination 04-11-2021: Updated recommendations for COVID-19 Vaccine 01-01-2023: 2023 vaccination calendar

Footnotes:

1. https://emvolio.gov.gr/
2. 2 doses of RV1 (month 2 and 4) OR 3 doses of RV5 (month 2, 4 and 6)
3. PPSV23 recommended from 2 years of age in at-risk groups
4. MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB vaccine is recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
5. 21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
6. for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
7. Vaccination is also recommended for infants and children up to the age of 5 years who belong to an increased risk groups and who have not been previously vaccinated
8. Babies born to a mother infected with hepatitis B (or with unknown status) will be offered a first vaccine dose at birth simultaneously with HB immunoglobulin. More details on follow-up schedule are available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
9. PPSV is recommended in addition to PCV13 or PCV15 at least 2 months after the last dose of PCV13 in subjects > 2 years with an increased risk of disease from pneumococcal infections. A booster dose of PPSV23 is recommended 5 years after the first dose
10. Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2023). 2 doses scheme up to 15 years with 6 months interval between doses, thereafter 3 doses. for specific at-risk groups vaccination can be extended up to 26 years.
11. 2 doses (RZV vaccine) in immunocompromised with 2 or more episodes of herpes-zoster

More information available at:
https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/


Last update : 16 May 2023